Trials / Completed
CompletedNCT00835978
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 213 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | axitinib | axitinib 5mg BID (open-label) + axitinib dose titration (blinded) |
| DRUG | axitinib | axitinib 5mg BID (open-label) + placebo dose titration (blinded) |
| DRUG | axitinib | axitinib 5mg BID (open-label) |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2012-10-01
- Completion
- 2016-02-01
- First posted
- 2009-02-04
- Last updated
- 2017-05-30
- Results posted
- 2014-05-26
Locations
65 sites across 6 countries: United States, Czechia, Germany, Japan, Russia, Spain
Source: ClinicalTrials.gov record NCT00835978. Inclusion in this directory is not an endorsement.